Travel-Related IllnessEOPNCT06701890
Observational Study of Travellers Pathologies
A study testing Blood sample collection and Fecal sample collection in people with Travel-Related Illness, run by Institut Pasteur at 1 site in France.
Trial summary
Traveling to emerging countries is associated with a significant risk of encountering health issues specific to the destination, such as gastrointestinal and respiratory infections, malaria episodes, and road traffic accidents.These conditions are associated with behavioral, geographical, or environmental risk… Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Travel-Related Illness
- What is being tested?
- Blood sample collection and Fecal sample collection
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 11,000 participants
- Where
- 1 siteFrance
- Study dates
- 9 Dec 2024to Dec 2036
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
- Inclusion Criteria :
- For all participants in the EOP study :
- Major subject (age ≥ 18)
- Owns a smartphone compatible with electronic data collection
- Preparing to travel outside mainland France
- Affiliated with or covered by Social Security or private insurance
- Willing to participate in the EOP study
- For the EOP-Arbo Sub-study :
- Subject who has consented to participate in the EOP_Arbo study.
- For the EOP-AMR Sub-study :
- Subject who has consented to participate in the EOP_AMR study.
- Exclusion Criteria:
- For all participants in the EOP study :
- Travel duration ≤ 3 days
- Travel duration > 12 months
- Person traveling as part of an expatriation without planned movement outside the settlement in the destination country
- Person under legal protection or unable to express consent for participation
- For the EOP-Arbo Sub-study :
- Individuals deemed clinically and/or biologically unfit by the investigator to undergo the blood samples required for the study.
- For the EOP-AMR Sub-study :
- No specific exclusion criteria.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Julia ABAD contact
France1 site, 1 recruiting
- Recruiting
Medical Center of Institut Pasteur
Paris, 75015
Fabien TAIEB, MD, fabien.taieb@pasteur.fr
About this study
Traveling to emerging countries is associated with a significant risk of encountering health issues specific to the destination, such as gastrointestinal and respiratory infections, malaria episodes, and road traffic accidents.These conditions are associated with behavioral, geographical, or environmental risk factors. A better understanding of these factors will enable the development of targeted recommendations to minimize travel related health issues.
The main objective of this study is to determine the incidence of pathologies occurring during travel outside the metropolitan territory.
Read the detailed description
Traveling to emerging countries is associated with a significant risk of encountering health issues specific to the destination, such as gastrointestinal and respiratory infections, malaria episodes, and road traffic accidents.These conditions are associated with behavioral, geographical, or environmental risk factors. A better understanding of these factors will enable the development of targeted recommendations to minimize travel related health issues.
The main objective of this study is to determine the incidence of pathologies occurring during travel outside the metropolitan territory.
Furthermore, two key aspects from a Public Health perspective are associated with travel and the globalization of exchanges: the acquisition of emerging pathogens or pathogens with antimicrobial resistance of concern.
To study these two aspects, the EOP study includes two sub-studies called EOP-Arbo and EOP-AMR.
- EOP-Arbo : The objective of this sub-study is to determine the risk of contracting an arboviral disease during travel, as well as the factors that may favor infection. For this, blood samples will be collected.
- EOP-AMR : The objective of this sub-study is to determine the risk of contracting an antibiotic-resistant bacteria during the trip. For this, faecal samples will be collected.
- Conditions
- Travel-Related Illness
- Being tested
- Blood sample collection, Fecal sample collection
- Keywords
- Travel, Risk Factors, Pathology, Arbovirose
- Medical subject headings
- Travel-Related Illness
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Blood sample collectionOther
16 mL at inclusion 16 mL at 1 month after return from travel
Fecal sample collectionOther
1 sample at inclusion
1 sample at day 1, day 7, day 14, day 21, 1 month and 2 month after return from travel
| Study group | Role | What they receive |
|---|---|---|
| Adults planning to travel outside metropolitan France. | Experimental | Human biological samples :
* Blood sample
* fecal sample Receives: Other: Blood sample collection; Other: Fecal sample collection |
What is being measured
The primary outcome is the main question the study is designed to answer.
Determine the incidence of pathologies occurring during a travel outside the metropolitan territory.
Number of subjects who developed a pathology during the travel among participants
Measured: 10 years
Secondary outcomes (2)
For EOP-Arbo sub-study : Determine the prevalence for the occurrence of an arboviral disease (dengue, chikungunya, Zika) during the travel.
Number of arboviral diseases (dengue, chikungunya, Zika) during the travel among participants
Measured: 10 years
For EOP-AMR sub-study : Determine the prevalence for the acquisition of multi-resistant bacteria (MRB) during the travel.
Proportion of subjects with multi-resistant bacteria acquired during the travel
Measured: 10 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Nov 2024
- Study start9 Dec 2024
- Primary completionDec 2034 (estimated)
- Study completionDec 2036 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Travel-Related IllnessStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 11,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Institut Pasteur
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Fabien TAIEB, MD, Principal investigator, Medical Center of Institut Pasteur
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06701890
- Sponsor's protocol ID
- 2022-069
- Other IDs
- 2023-A02574-41
- Acronym
- EOP
- Status last verified
- Apr 2025
- First submitted
- 20 Nov 2024
- Last updated
- 1 May 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 1 May 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Observational Study of Travellers Pathologies
- ClinicalTrials.gov ID
- NCT06701890
- Acronym / sponsor ID
- EOP / 2022-069
- Conditions
- Travel-Related Illness
- Keywords
- Travel, Risk Factors, Pathology, Arbovirose
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 11,000 participants (estimated)
- Lead sponsor
- Institut PasteurIndustry (pharma, biotech, devices)
- Study start
- 9 Dec 2024 (actual)
- Primary completion
- Dec 2034 (estimated)
- Study completion
- Dec 2036 (estimated)
- First posted
- 22 Nov 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Traveling to emerging countries is associated with a significant risk of encountering health issues specific to the destination, such as gastrointestinal and respiratory infections, malaria episodes, and road traffic accidents.These conditions are associated with behavioral, geographical, or environmental risk factors. A better understanding of these factors will enable the development of targeted recommendations to minimize travel related health issues.
The main objective of this study is to determine the incidence of pathologies occurring during travel outside the metropolitan territory.
Detailed description
Traveling to emerging countries is associated with a significant risk of encountering health issues specific to the destination, such as gastrointestinal and respiratory infections, malaria episodes, and road traffic accidents.These conditions are associated with behavioral, geographical, or environmental risk factors. A better understanding of these factors will enable the development of targeted recommendations to minimize travel related health issues.
The main objective of this study is to determine the incidence of pathologies occurring during travel outside the metropolitan territory.
Furthermore, two key aspects from a Public Health perspective are associated with travel and the globalization of exchanges: the acquisition of emerging pathogens or pathogens with antimicrobial resistance of concern.
To study these two aspects, the EOP study includes two sub-studies called EOP-Arbo and EOP-AMR.
- EOP-Arbo : The objective of this sub-study is to determine the risk of contracting an arboviral disease during travel, as well as the factors that may favor infection. For this, blood samples will be collected.
- EOP-AMR : The objective of this sub-study is to determine the risk of contracting an antibiotic-resistant bacteria during the trip. For this, faecal samples will be collected.
Study design
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Adults planning to travel outside metropolitan France. | Experimental | Other: Blood sample collection, Other: Fecal sample collectionHuman biological samples : * Blood sample * fecal sample |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Blood sample collection16 mL at inclusion 16 mL at 1 month after return from travel | Other | Adults planning to travel outside metropolitan France. |
| Fecal sample collection1 sample at inclusion 1 sample at day 1, day 7, day 14, day 21, 1 month and 2 month after return from travel | Other | Adults planning to travel outside metropolitan France. |
Primary outcome
Determine the incidence of pathologies occurring during a travel outside the metropolitan territory.
Time frame: 10 years
Number of subjects who developed a pathology during the travel among participants
2 secondary outcomes
For EOP-Arbo sub-study : Determine the prevalence for the occurrence of an arboviral disease (dengue, chikungunya, Zika) during the travel.
Time frame: 10 years
For EOP-AMR sub-study : Determine the prevalence for the acquisition of multi-resistant bacteria (MRB) during the travel.
Time frame: 10 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 May 2025.
- Individual participant dataSharing planned: Undecided
Related trials for Travel-Related Illness
Active, not recruiting
Vaccination Nudges From Pharmacists
Stroke, Influenza Human
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Julia ABAD contact
Fabien TAIEB, MD principal investigator
Medical Center of Institut Pasteur
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Blood sample collection and Fecal sample collection in people with Travel-Related Illness, run by Institut Pasteur at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 1 May 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Fabien TAIEB, MD (0140613456 ext. +33, fabien.taieb@pasteur.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Determine the incidence of pathologies occurring during a travel outside the metropolitan territory. (time frame: 10 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 May 2025.